Ipsen S.A. (IPSEY)
| Previous Close | 30.80 |
| Open | 30.92 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 30.92 - 30.92 |
| 52 Week Range | 26.97 - 34.34 |
| Volume | |
| Avg. Volume | 1,691 |
| Market Cap | 10.24B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | 15.61 |
| EPS (TTM) | 1.98 |
| Earnings Date | Jul 24, 2024 |
| Forward Dividend & Yield | 0.32 (1.04%) |
| Ex-Dividend Date | Jun 02, 2023 |
| 1y Target Est | N/A |
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 30 April 2024 83,814,526 Gross total* of voting rights: 132,102,659 Net total*
- GlobeNewswire
Ipsen appoints Keira Driansky as EVP, President of North America
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executive Leadership Team (ELT) and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “We are thrilled to welcome Keira to Ipsen as our new President of North America as she brings extensive experience in the life sciences industry
- GlobeNewswire
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Q1 2024 Q1 2023 % change €m €m ActualCER1Growth platforms2509.7452.012.8%16.2%New medicines345.514.3n/an/aSomatuline®257.8263.2-2.0%-1.3%Other9.512.4-23.8%-20.5%Total Sales822.4741.910.9%13.3% Highlights Total-sales growth of 13.3% at CER1, or 10.9% as reported, driven by the 16.2%1 increase in sales of the growth platforms2
